Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
NIHR Journals Library
2011-12-01
|
| Series: | Health Technology Assessment |
| Online Access: | https://doi.org/10.3310/hta15420 |
| id |
doaj-16eb17f4b6834235a13e79e99f5fa2d8 |
|---|---|
| record_format |
Article |
| spelling |
doaj-16eb17f4b6834235a13e79e99f5fa2d82020-11-25T00:15:25ZengNIHR Journals LibraryHealth Technology Assessment1366-52782011-12-01154210.3310/hta15420Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysisN Fleeman0A BagustA BolandR DicksonY DundarM MoonanJ OyeeM BlundellH DavisA ArmstrongN ThorpLiverpool Reviews and Implementation Group (LRiG), University of Liverpool, Liverpool, UKhttps://doi.org/10.3310/hta15420 |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
N Fleeman A Bagust A Boland R Dickson Y Dundar M Moonan J Oyee M Blundell H Davis A Armstrong N Thorp |
| spellingShingle |
N Fleeman A Bagust A Boland R Dickson Y Dundar M Moonan J Oyee M Blundell H Davis A Armstrong N Thorp Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis Health Technology Assessment |
| author_facet |
N Fleeman A Bagust A Boland R Dickson Y Dundar M Moonan J Oyee M Blundell H Davis A Armstrong N Thorp |
| author_sort |
N Fleeman |
| title |
Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis |
| title_short |
Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis |
| title_full |
Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis |
| title_fullStr |
Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis |
| title_full_unstemmed |
Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis |
| title_sort |
lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (her2): a systematic review and economic analysis |
| publisher |
NIHR Journals Library |
| series |
Health Technology Assessment |
| issn |
1366-5278 |
| publishDate |
2011-12-01 |
| url |
https://doi.org/10.3310/hta15420 |
| work_keys_str_mv |
AT nfleeman lapatinibandtrastuzumabincombinationwithanaromataseinhibitorforthefirstlinetreatmentofmetastatichormonereceptorpositivebreastcancerwhichoverexpresseshumanepidermalgrowthfactor2her2asystematicreviewandeconomicanalysis AT abagust lapatinibandtrastuzumabincombinationwithanaromataseinhibitorforthefirstlinetreatmentofmetastatichormonereceptorpositivebreastcancerwhichoverexpresseshumanepidermalgrowthfactor2her2asystematicreviewandeconomicanalysis AT aboland lapatinibandtrastuzumabincombinationwithanaromataseinhibitorforthefirstlinetreatmentofmetastatichormonereceptorpositivebreastcancerwhichoverexpresseshumanepidermalgrowthfactor2her2asystematicreviewandeconomicanalysis AT rdickson lapatinibandtrastuzumabincombinationwithanaromataseinhibitorforthefirstlinetreatmentofmetastatichormonereceptorpositivebreastcancerwhichoverexpresseshumanepidermalgrowthfactor2her2asystematicreviewandeconomicanalysis AT ydundar lapatinibandtrastuzumabincombinationwithanaromataseinhibitorforthefirstlinetreatmentofmetastatichormonereceptorpositivebreastcancerwhichoverexpresseshumanepidermalgrowthfactor2her2asystematicreviewandeconomicanalysis AT mmoonan lapatinibandtrastuzumabincombinationwithanaromataseinhibitorforthefirstlinetreatmentofmetastatichormonereceptorpositivebreastcancerwhichoverexpresseshumanepidermalgrowthfactor2her2asystematicreviewandeconomicanalysis AT joyee lapatinibandtrastuzumabincombinationwithanaromataseinhibitorforthefirstlinetreatmentofmetastatichormonereceptorpositivebreastcancerwhichoverexpresseshumanepidermalgrowthfactor2her2asystematicreviewandeconomicanalysis AT mblundell lapatinibandtrastuzumabincombinationwithanaromataseinhibitorforthefirstlinetreatmentofmetastatichormonereceptorpositivebreastcancerwhichoverexpresseshumanepidermalgrowthfactor2her2asystematicreviewandeconomicanalysis AT hdavis lapatinibandtrastuzumabincombinationwithanaromataseinhibitorforthefirstlinetreatmentofmetastatichormonereceptorpositivebreastcancerwhichoverexpresseshumanepidermalgrowthfactor2her2asystematicreviewandeconomicanalysis AT aarmstrong lapatinibandtrastuzumabincombinationwithanaromataseinhibitorforthefirstlinetreatmentofmetastatichormonereceptorpositivebreastcancerwhichoverexpresseshumanepidermalgrowthfactor2her2asystematicreviewandeconomicanalysis AT nthorp lapatinibandtrastuzumabincombinationwithanaromataseinhibitorforthefirstlinetreatmentofmetastatichormonereceptorpositivebreastcancerwhichoverexpresseshumanepidermalgrowthfactor2her2asystematicreviewandeconomicanalysis |
| _version_ |
1725386941349756928 |